- Home
- MTG vs MIRM Comparison
MTG vs MIRM Comparison
Compare MTG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTG | MIRM |
|---|---|---|
| Founded | 1957 | 2018 |
| Country | United States | United States |
| Employees | 542 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.7B |
| IPO Year | 2008 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MTG | MIRM |
|---|---|---|
| Price | $26.36 | $94.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $28.50 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 2.1M | 916.0K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | 8.65 | ★ 74.59 |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $1,213,636,000.00 | $19,138,000.00 |
| Revenue This Year | $2.50 | $26.22 |
| Revenue Next Year | $1.77 | $22.04 |
| P/E Ratio | $34.03 | ★ N/A |
| Revenue Growth | ★ 0.49 | N/A |
| 52 Week Low | $25.23 | $42.89 |
| 52 Week High | $29.97 | $114.99 |
Technical Indicators
Market Signals| Indicator | MTG | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 44.99 | 43.82 |
| Support Level | $25.78 | $87.26 |
| Resistance Level | $27.64 | $98.03 |
| Average True Range (ATR) | 0.66 | 7.01 |
| MACD | -0.14 | -0.39 |
| Stochastic Oscillator | 21.92 | 27.63 |
Price Performance
Historical ComparisonAbout MTG MGIC Investment Corporation
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection account for close to the majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia, and New York.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.